August 15, 2012Open Access

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Key Points

Key points are not available for this paper at this time.

Abstract

Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Howard I. Scher

Karim Fizazi

Fred Saad

Journals

New England Journal of Medicine

Actions

Institutions

Cornell University

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study